Pfizer Stock News

About 100,000 doses of Pfizer’s COVID-19 vaccine may be destroyed by the end of this month (March). This is due to the dwindling interest in patronage on the part of citizens, South African (SA) health authorities said on Friday.

The European Medicines Agency''s ((EMA)) leading vaccine expert Marco Cavaleri played down the impact of recent findings in New York over the decline of protection generated by…

Pfizer (PFE) Canada is recalling blood pressure therapy, Accuretic due to the presence of a potential cancer-causing impurity called nitrosamine above the acceptable level, the…

About 100,000 doses of Pfizer''s Covid-19 vaccine are at risk of being destroyed by the end of this month due to slow uptake by citizens, health authorities said on Friday.

JOHANNESBURG (Reuters) – About 100,000 doses of Pfizer’s COVID-19 vaccine are at risk of being destroyed by the end of this month due to slow uptake by citizens, South African health authorities said on Friday.

Major companies in the pharmaceuticals market include Johnson & Johnson, Novartis AG, Bristol-Myers Squibb, AbbVie, Sanofi S. A, Pfizer Inc. , GlaxosmithKline, F. Hoffmann-La Roche Ltd. , Merck & Co. and AstraZeneca. Major companies in the pharmaceuticals market include Johnson & Johnson, Novartis AG, Bristol-Myers Squibb, AbbVie, Sanofi S. A, Pfizer Inc. , GlaxosmithKline, F. Hoffmann-La Roche Ltd. , Merck & Co. and AstraZeneca.

Major players in the vaccine market are AstraZeneca, Emergent Biosolutions, Glaxosmithkline, Merck, Pfizer, Sanofi Pasteur, Abbott, Astellas Pharma, Bavarian Nordic, CSL Limited, Daiichi Sankyo Company, Johnson & Johnson, Mitsubishi Tanabe Pharma Corporation, Serum Institute of India, Takeda Pharmaceutical Co. Major players in the vaccine market are AstraZeneca, Emergent Biosolutions, Glaxosmithkline, Merck, Pfizer, Sanofi Pasteur, Abbott, Astellas Pharma, Bavarian Nordic, CSL Limited, Daiichi Sankyo Company, Johnson & Johnson, Mitsubishi Tanabe Pharma Corporation, Serum Institute of India, Takeda Pharmaceutical Co.

Digital Brownshirts And Their Masters Authored by David Souto Alcalde and Thomas Harrington via Thee Brownstone Institute, We are under siege. A nihilistic fanaticism is running free among us thanks to the emergence of a journalistic “ethos” that establishes an almost complete equivalence between the “truth” and those utterances that support the strategic goals of the great economic and digital powers of our time. A few months ago Facebook censored an article in the British Medical Journal that highlighted serious irregularities in Pfizer’s clinical vaccine trials. Then two weeks ago, fact-checkers from the Spanish websites Newtral and Maldita burst into the public square to accuse professor of Pharmacology, renowned expert in drug safety, and ex-WHO adviser, Joan Ramón Laporte of foisting lies and disinformation onto the Spanish populace. This, in reaction to Laporte’s testimony before a Spanish parliamentary commission investigating the country’s vaccination effort. Despite his towering credentials, his intervention was quickly tarred as problematic by the media and subsequently banned by YouTube.

Washington, DC, March 03, 2022 (GLOBE NEWSWIRE) -- In a 55,000-page set of documents released on Tuesday, the U.S. Food and Drug Administration''s (FDA''s) Center for Biologics Evaluation and Research (CBER) is for the first time allowing the public to access data Pfizer submitted to FDA from its clinical trials in support of a COVID-19 vaccine license. This follows U.S. District Judge Mark T. Pittman''s decision on January 6 to deny the request from the FDA to suppress the data for the next 75 years which the agency claimed was necessary, in part, because of its " limited resources ." A 38-page report included in the documents features an Appendix, "LIST OF ADVERSE EVENTS OF SPECIAL INTEREST," that lists 1,291 different adverse events following vaccination. The list includes acute kidney injury, acute flaccid myelitis, anti-sperm antibody positive, brain stem embolism, brain stem thrombosis, cardiac arrest, cardiac failure, cardiac ventricular thrombosis, cardiogenic shock, central nervous system vasculitis, death neonatal, deep vein thrombosis, encephalitis brain stem, encephalitis hemorrhagic, frontal lobe epilepsy, foaming at mouth, epileptic psychosis, facial paralysis, fetal distress syndrome, gastrointestinal amyloidosis, generalized tonic-clonic seizure, Hashimoto''s encephalopathy, hepatic vascular thrombosis, herpes zoster reactivation, immune-mediated hepatitis, interstitial lung disease, jugular vein embolism, juvenile myoclonic epilepsy, liver injury, low birth weight, multisystem inflammatory syndrome in children, myocarditis, neonatal seizure, pancreatitis, pneumonia, stillbirth, tachycardia, temporal lobe epilepsy, testicular autoimmunity, thrombotic cerebral infarction, Type …

OTTAWA, ON , March 3, 2022 /CNW/ - Summary Products: Accuretic (quinapril hydrochloride and hydrochlorothiazide) Issue: All lots are being recalled due to the presence of a nitrosamine impurity above the acceptable level for long-term use. What to do: Continue taking your medication unless you have been advised to stop by your health care provider. Not treating your condition may pose a greater health risk. Contact your health care provider to discuss other treatment options. Issue Pfizer Canada ULC is recalling all lots of Accuretic (quinapril hydrochloride and hydrochlorothiazide) medication in 10/12.5 mg, 20/12.5 mg and 20/25 mg strengths due to the presence of a nitrosamine impurity ( N -nitroso-quinapril) above the acceptable level. Accuretic is a prescription drug used to treat high blood pressure. It contains a combination of quinapril hydrochloride and hydrochlorothiazide, which both lower blood pressure. Long-term exposure to N -nitroso-quinapril at a level above what is considered acceptable may increase the risk of cancer.

The Swedish study suggests the vaccine is capable of becoming DNA, which is what the CDC claimed would not happen.

The White House plans to make up to 1 million of Pfizer''s antiviral pills available to pharmacies later this month.

‘Test to Treat’ ignores the significant risk of drug interactions with the Pfizer pill.

Pfizer Inc. (NYSE:PFE) price on Thursday, March 03, rose 0.93% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $48.14. A look at the stock’s price movement, the level at last check in today’s session was $47.70, moving within a range at $46.00 and $47.93. The beta value … Pfizer Inc. (PFE) Has A Potential Gold Mine Read More »

Market analysts are debating what future Covid vaccine demand will look when Covid becomes an endemic, seasonal virus.